Krystal Biotech, Inc. (KRYS) Return on equity 2021–2025
Krystal Biotech, Inc. (KRYS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
16.8%FY2025 · since FY2021: -11.7% → 16.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 16.8% | +7.4 pp |
| FY2024 | 9.4% | +8.0 pp |
| FY2023 | 1.4% | +28.2 pp |
| FY2022 | -26.8% | -15.1 pp |
| FY2021 | -11.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice